Viking Therapeutics (VKTX) saw its stock price plummet 40.62% in pre-market trading on Tuesday, despite announcing positive results from its Phase 2 clinical trial for its oral weight-loss drug, VK2735. The sharp decline highlights a significant disconnect between the trial outcomes and investor expectations.

According to the company's announcement, VK2735 helped patients with obesity lose an average of 12.2% of their body weight over a 13-week period. This result falls within the 10% to 15% range that analysts had anticipated and surpasses the 8.2% weight loss observed in an earlier trial. Additionally, Viking Therapeutics stated that the study achieved its endpoints and that VK2735 was shown to be safe and well-tolerated during the study period.

However, the market's negative reaction suggests that investors may have been hoping for even more impressive results. The competitive landscape for weight-loss drugs is intensifying, with several pharmaceutical companies vying for market share. It's possible that while VK2735's performance was solid, it may not have been perceived as groundbreaking enough to give Viking a significant edge over its rivals. Additionally, concerns about the discontinuation rate, with 38% of participants in the highest dose group stopping treatment early, may have contributed to the stock's decline. As the trading day progresses, it remains to be seen whether Viking Therapeutics can address investor concerns and potentially recover from this pre-market plunge.